Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnology with electronics comes with on-board sensors that enable clinicians to monitor and control an implant’s drug production process.
The post This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’ appeared first on MedCity News.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
